Introduction
The US Hemp Roundtable — one of the industry’s leading advocacy organizations — has put a number on the scope of the November 12, 2026 compliance cliff: 95%. That’s the estimated share of currently available hemp products that will not meet the new federal standard and will be prohibited from general retail sale as of November 12.
Ninety-five percent. That is not a market correction. That is a market restructuring.
For B2B hemp ingredient suppliers and the brands they serve, understanding the full scale of this disruption — and what it means for the surviving 5% — is the most important strategic exercise of 2026.
Where the 95% Number Comes From
The new federal hemp definition, enacted through the 2025 Continuing Resolution, imposes two primary compliance requirements that together eliminate the vast majority of current hemp products:
1. The total THC container limit of 0.4mg. This applies to all hemp-derived consumable products. The 0.4mg threshold is extraordinarily low — a single standard hemp gummy with even modest THC content can exceed it. When you apply this limit across the full spectrum of hemp-derived products currently on the market — tinctures, edibles, beverages, vapes, flower — the vast majority fail.
2. The exclusion of converted and semi-synthetic cannabinoids. Products containing delta-8 THC, delta-10, THCO, hexahydrocannabinol, and other cannabinoids produced through chemical conversion are excluded from the hemp definition entirely. These categories represent a substantial portion of the current hemp retail market.
Combined, these two requirements eliminate nearly everything that isn’t a non-intoxicating CBD or CBG product with extremely low residual THC.
What the Surviving 5% Looks Like
The products and ingredients that survive the November 12 compliance cliff share common characteristics:
- Non-intoxicating cannabinoid profile: CBD, CBG, CBN, and other non-THC-class cannabinoids as the primary active ingredients
- Total THC at or below 0.4mg per container: Achievable with CBD isolate or carefully formulated broad-spectrum extracts
- Naturally derived cannabinoids: No converted or semi-synthetic compounds
- Full documentation: COAs from accredited labs showing total THC compliance
This is the market that survives — and it is the market that Low Gravity Hemp and its B2B customers are built for.
The Opportunity Inside the Disruption
A 95% product elimination sounds catastrophic. For brands on the wrong side of that number, it is. But for brands already operating in the compliant 5%, the disruption creates an extraordinary market opportunity:
Shelf space clears dramatically. Retailers that have been managing hemp sections filled with a mix of compliant and non-compliant products will be left with nearly empty planograms after November 12. The brands with compliant products ready to ship will have unprecedented access to that space.
Consumer demand doesn’t disappear. The tens of millions of Americans who currently buy hemp wellness products will not stop wanting them on November 12. They will migrate to whatever compliant options are available. Brands that are there — with the right products, in the right channels, with the right documentation — will capture that demand.
Supplier consolidation accelerates. With 95% of products exiting the market, the ingredient suppliers who served those products will also contract. Suppliers who are already positioned in the compliant segment — with the documentation and quality systems to support it — will gain market share as their lower-quality competitors exit.
Brand trust rebuilds. Years of market confusion created by inconsistent product quality and compliance will clear with the exit of the non-compliant majority. The brands left standing will inherit a cleaner consumer trust environment.
What This Means for B2B Ingredient Sourcing Right Now
If 95% of the current market is exiting, the ingredient sourcing implications are significant:
The demand signal for compliant ingredients is about to surge. As brands scramble to reformulate surviving SKUs and launch new compliant products, demand for CBD isolate, broad-spectrum distillate with verified non-detect THC, CBG isolate, and water-soluble hemp ingredients will spike.
Supply of compliant ingredients may tighten. The suppliers who have been producing compliant-grade ingredients will face increased demand from a much larger pool of buyers. Brands that lock in supply agreements now — before the November surge — will have better pricing and availability than those who wait.
Quality documentation becomes the bottleneck. The constraint in the compliant market won’t be ingredient availability — it will be the availability of suppliers who can produce the documentation that healthcare, pharmacy, and premium retail channels require. That documentation takes time to build.
🌿 LGH Perspective
The 95% number is sobering, but it’s not surprising to us. We’ve been building for the compliant 5% since day one. Our entire ingredient portfolio — CBD isolate, broad-spectrum distillate, CBG isolate, water-soluble hemp — is designed to survive and thrive in the post-November 12 market. Our B2B customers aren’t in the 95%. They’re in the 5% that wins.
Final Thoughts
The US Hemp Roundtable’s 95% estimate is a clarifying data point. It quantifies what many in the industry have suspected but few have said explicitly: the November 12 deadline is not a speed bump. It is a fundamental restructuring of the hemp retail market. For brands that understand this and act accordingly — reformulating, re-sourcing, re-documenting — the restructuring is an opportunity. For those that don’t, it’s an exit.
Is your brand in the 5% that survives? Contact Low Gravity Hemp to make sure your ingredient sourcing is ready.
